It has been a long road to market for AVEO Pharmaceuticals, Inc.'s Fotivda (tivozanib), but the company sees an opportunity for the tyrosine kinase inhibitor in the third-line renal cell carcinoma setting where there are currently no approved options, and also views Fotivda’s tolerability profile as a potential advantage.
After years of back-and-forth with the US Food and Drug Administration, the 10 March approval is for a narrower indication – third-line treatment for relapsed/refractory advanced RCC –
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?
